|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Privacy, Pediatrics, and Policy
FDA proposals for expanding the pediatric study program include tax incentives and }transferable exclusivity.}
Advertisement
Articles in this issue
about 25 years ago
Research: New Horizonsabout 25 years ago
Earnings: Tough Times Aheadabout 25 years ago
Outbreak: Anthrax Alarmabout 25 years ago
Patents: China on the Genome Mapabout 25 years ago
Lilly's International Familyabout 25 years ago
Update: Punishment and Reprieveabout 25 years ago
Shortage: Vaccine Worriesabout 25 years ago
Gateway to Japanabout 25 years ago
SurroundedAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
2
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
Pharmaceutical Executive Daily: FDA Approves Datroway
5